Product Highlight - Enhertu

EXTEND HER2+ EXPECTATIONS
ENHERTU^® achieved unprecedented efficacy with consistent and durable responses^1,2
• Confirmed ORR 61.4% (n=113; 95% CI, 54.0, 68.5) = 6.5% CR (n=12) + 54.9% PR (n=101)^*†1,2
• mPFS=19.4 months (95% CI: 14.1, NE)^*‡1,2

* ENHERTU^® was assessed in a single-arm trial of 184 females (DESTINY-Breast01) with HER2-positive unresectable and/or mBC who had received 2 prior anti-HER2 therapies. Patients received ENHERTU^® 5.4 mg/kg IV Q3W until disease progression or unacceptable toxicity.
† ORR (CR + PR) in ITT population
‡ Disease progression was assessed using modified RECIST v1.1.2

ENHERTU^® is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

References:
1. Modi S, et al. N Engl J Med. 2020;382(7):610-62
2. Cancer Res 2021;81(4 Suppl): Abstract no. PD3-06.